University Hospital Zurich
Zurich, Canton of Zurich, 8091, Switzerland
Location status: Recruiting
Location contact
Lukas Otto, Dr.
CONTACT
Susanne Wegener, Prof.
CONTACT
NCT Number: NCT06530927
Stroke remains a major health burden worldwide. Many patients are severely disabled and stay in need of care. Mechanical thrombectomy has dramatically improved outcomes for stroke patients with large vessel occlusions, yet 40-50% of patients with successful recanalization remain severely disabled despite successful recanalization, a scenario called "futile recanalization". One of the causes for this lack of treatment effect is capillary obstruction, or "no reflow", potentially resulting from activated neutrophils and micrometer-sized blood clots. To address this issue, we employ digital holotomographic and atomic force microscopy to investigate the structural and chemical characteristics of blood and clot material in stroke patients and individuals at high risk of developing a stroke. Our study elucidates the association of activated neutrophils and microclots with stroke risk, and may be associated with clinical outcome, stroke ethology and reperfusion failure in patients with stroke. Leveraging label-free microscopy tools, could potentially lead to the discovery of new biomarkers for individualized stroke treatment and prevention, ultimately offering rapid identification of at risk patients and improving clinical outcomes
Interested in participating?
Request Info18 year and older
All sexes
Observational
Zurich, Canton of Zurich, 8091, Switzerland
Location status: Recruiting
Lukas Otto, Dr.
CONTACT
Susanne Wegener, Prof.
CONTACT
Background:
Stroke remains a major health burden worldwide. Many patients are severely disabled and stay in need of care. Since introducing mechanical thrombectomy as a therapeutic option, clinical outcome has drastically improved over the last few years. However, despite successful macrovascular reperfusion (recanalization), patients with stroke still have a significant risk (about 40-50%) of remaining severely disabled, a scenario called "futile recanalization". One of the causes for this lack of treatment effect is capillary obstruction, or "no reflow", potentially resulting from activated neutrophils and micrometer-sized blood clots. Previous work in rodent stroke models demonstrated that removal of these capillary stalls indeed improves reperfusion and recovery after stroke. However, there is a lack of knowledge regarding the role of neutrophils or microclots in patients with stroke, and their potential to indicate reperfusion failure.
Aim:
The goal of our study is to search for activated neutrophils and microclots in peripheral blood samples from patients with stroke. We anticipate that neutrophil and microclot characteristics such as size, shape, or surface structure may indicate stroke risk, and may be associated with clinical outcome, stroke ethology and reperfusion failure in patients with stroke. Our goal is to improve the prediction of stroke risk and treatment success.
Methodology:
We plan to prospectively include 500 patients with acute and chronic stroke, as well as a control group. We have teamed up with biophysicists from the Swiss Federal Laboratories for Materials Science (EMPA) using the novel microscopic tools 3D rotational digital tomography (DHTM) to achieve an unprecedented resolution of less than 10 μm for detection of altered neutrophil phenotypes and microclots in peripheral blood samples. Furthermore, in patients undergoing mechanical thrombectomy, retrieved clots will be analyzed with high-density micro-computertomography (micro-CT). Quantity, mechanical and structural properties of microclots and neutrophils will be correlated with risk of reperfusion failure, stroke recurrence and clinical recovery. Analyses of clots from patients with large vessel occlusion will be used to derive risk of reperfusion failure along with most likely source of the clot, and thus, most likely stroke etiology.
Potential Significance:
Current diagnostic tools are insufficient to predict response to treatment, clot source or stroke recurrence risk. Our project has the potential to discover new, clinically applicable biomarkers identifying patients at risk within a few hours, enabling individualized stroke treatment and prevention.
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Patients without acute stroke CS or CSG
Patients with acute stroke (AS-noTx, AS-IVT, AS-MT):
Exclusion criteria
All groups:
Acute Stroke no Therapy
Acute Stroke IVT-Group • Acute treatment with MT or without IVT
Acute Stroke MT-Group
DHTM is label-free and records the phase shift of low-energy light passing through the specimen on a transparent surface with minimal perturbation. DHTM measures the refractive index (RI) and computes the refractive index gradient (RIG), unveiling optical heterogeneity in cells. We will analyze blood samples for the detection of altered neutrophil phenotypes and microclots.
The atomic force microscope (AFM) is widely used in materials science and has found many applications in biological sciences but has been limited in use in vision science. The AFM can be used to image the topography of soft biological materials in their native environments. We will analyze blood samples for the detection of altered neutrophil phenotypes and microclots
Micro-CT is a 3D imaging technique utilizing X-rays to see inside an object, slice by slice. Micro-CT, also called microtomography or micro computed tomography, is similar to hospital CT or "CAT" scan imaging but on a small scale with greatly increased resolution. Samples can be imaged with pixel sizes as small as 100 nanometers and objects can be scanned as large as 200 millimeters in diameter. We will use micro-CT to analyze blood clots from patients with large vessel occlusion.
Time frame: First Visit/Admission and patients with acute stroke after 24 hours, 3 months and 1 year
3D rotational digital tomography and atomic force microscopy
imaging outcome measurements:
Time frame: First Visit/Admission and patients with acute stroke after 24 hours, 3 months and 1 year
3D rotational digital tomography and atomic force microscopy
image morphological outcome measurements:
Time frame: <24 hours in patients with mechanical thrombectomy
Defined by successfull macrovascular reperfusion (TICI >=2c) and insufficient microvascular reperfusion with the outcome measurment (yes/no)
Successfull macrovasular reperfusion is defined according to the mTICI score 2c or 3.
Microvascular reperfusion success will be evaluated with thresholds were used to discriminate between microvascular hypoperfusion and reperfusion, calculated from perfusion images obtained on computed tomography (CTP) or magnetic resonance perfusion imaging (MRP).
Time frame: First Visit/Admission and patients with acute stroke after 24 hours, 3 months and 1 year
will be assessed using National Institutes of Health Stroke Scale (NIHSS)
NIHSS
13 assessed functional domains Range 0-42, higher score indicates severe impairment
Time frame: First Visit/Admission and patients with acute stroke after 24 hours, 3 months and 1 year
will be assessed using modified Rankin Scale (mRS)
mRS
Range: (0-6) 0 = no symptoms, 6 = death, higher score indicates severe impairment
Time frame: 365 days
EQ-5D-5L
Evaluation of 5 different aspects of health with likert scale (1-5)
MOBILITY SELF-CARE USUAL ACTIVITIES PAIN / DISCOMFORT ANXIETY / DEPRESSION Each domain is scored individually, higher values indicate higher impairment of quality of life
Time frame: 365 days
Stroke, heart attack, brain bleeding
Time frame: 365 days
Mortality
Contact information is provided by the study sponsor or research team.
Lukas Otto, Dr. med.
CONTACT
Susanne Wegener, Prof.
CONTACT
University of Zurich
Other
Micro-clots and Neutrophil Activation as Potential Indicators for Stroke Risk and Reperfusion Failure The CLOTSAFE - Study (Micro-CLOTs, Stroke Risk, Activated Neutrophils, Reperfusion FailurE)
Acronym: CLOTSAFE
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07345702
Basilar Artery Occlusion, Brain Diseases
Beijing, Beijing Municipality, China
View Trial DetailsNCT05032053
Brain Diseases, Cardiovascular Diseases
Ankang, Shaanxi, China
View Trial DetailsNCT07736885
Brain Diseases, Cardiovascular Diseases
Tianjin, Tianjin Municipality, China
View Trial DetailsNCT07731087
Brain Diseases, Cardiovascular Diseases
Makassar, South Sulawesi, Indonesia
View Trial Details